Proteomics integrated with Escherichia coli vector-based vaccines and antigen microarrays reveals the immunogenicity of a surface sialidase-like protein of Propionibacterium acnes (original) (raw)
Related papers
Proteomics for development of vaccine
Journal of …, 2011
The success of genome projects has provided us with a vast amount of information on genes of many pathogenic species and has raised hopes for rapid progress in combating infectious diseases, both by construction of new effective vaccines and by creating a new generation of therapeutic drugs. Proteomics, a strategy complementary to the genomic-based approach, when combined with immunomics (looking for immunogenic proteins) and vaccinomics (characterization of host response to immunization), delivers valuable information on pathogen-host cell interaction. It also speeds the identification and detailed characterization of new antigens, which are potential candidates for vaccine development. This review begins with an overview of the global status of vaccinology based on WHO data. The main part of this review describes the impact of proteomic strategies on advancements in constructing effective antibacterial, antiviral and anticancer vaccines. Diverse aspects of disease mechanisms and disease preventions have been investigated by proteomics.
Proteomic technology in the design of new effective antibacterial vaccines
Expert Review of Proteomics, 2009
Infectious diseases still remain the main cause of human premature deaths, especially in developing countries. Vaccines constitute the most cost-effective tool for prophylaxis of infectious diseases. Elucidation of the complete genomes of many bacterial pathogens has provided a new blueprint for the search of novel vaccine candidates. At the same time, it was a turning point in the development of transcriptomics and proteomics. This article concentrates on the proteomic contribution to vaccinology, pointing out relationships between genomic, transcriptomic and proteomic approaches and describing how they complement one another. It also highlights the recent proteomic techniques applied to antigen identification, their capabilities and limitations, as well as the strategies that are taken to overcome technical difficulties and to refine applied methods. Finally, some recent experimental data concerning the proteomic/immunoproteomic influence on identification of vaccine candidates to prevent human infections caused by Streptococcus spp., as well as by a major bioterrorist agent, Bacillus anthracis is presented.
Vaccine, 2000
The ability of bioinformatics to characterize genomic sequences from pathogenic bacteria for prediction of genes that may encode vaccine candidates, e.g. surface localized proteins, has been evaluated. By applying appropriate tools for genomic mining to the published sequence of Haemophilus influenzae Rd genome, it was possible to identify a putative vaccine candidate, the outer membrane lipoprotein, P6. Proteomics complements genomics by offering abilities to rapidly identify the products of predicted genes, e.g. proteins in outer membrane preparations. The ability to identify the P6 protein uniquely from entries in a sequence database from the expected peptide-mass fingerprint of P6 demonstrates the power of proteomics. The application of proteomics for identification of vaccine candidates for another pathogenic bacterium, Helicobacter pylori using two different approaches is described. The first involves rapid identification of a series of monoclonal antibody reactive proteins from N-terminal sequence tags. The other approach involves identification of proteins in outer membrane preparations by 2-D electrophoresis followed by trypsin digestion and peptide mass map analysis. Our combined studies demonstrate that utilization of genome sequences by application of bioinformatics through genomics and proteomics can expedite the vaccine discovery process by rapidly providing a set of potential candidates for further testing.
New ways to identify novel bacterial antigens for vaccine development
Veterinary Microbiology, 2008
This article provides an overview of developments in approaches to identify novel bacterial components for use in recombinant subunit vaccines. In particular it describes the processes involved in ''reverse vaccinology'', and some associated complementary technologies such as proteomics that can be used in the identification of new and potentially useful vaccine antigens. Results obtained from the application of these new methods are forming a basis for a new generation of vaccines for use in the control of bacterial infections of humans and animals. #
The Antigenome: From Protein Subunit Vaccines to Antibody Treatments of Bacterial Infections?
Advances in Experimental Medicine and Biology, 2009
N ew strategies areneeded to masterinfectiousdiseases.Theso-called"passive vaccinat ion", i.e.,preventionand treatment with specific antibodies,hasa provenrecordand potential in the managementof infectionsand entered the medicalarenamore than 100yearsago. Progress in the identificationofspecific antigenshas becomethe hallmarkin the developmentof novelsubunit vaccines that often contain only a singleimmunogen,frequentlyproteins, derived from the microbe in order to induce protective immunity. On the other hand, the monoclonal antibodytechnology has enabledbiotechnology to produceantibodyspecies in unlimitedquantities and at reasonable coststhat are more or less identicalto their human counterparts and bind with high affinityto only one specific site of a givenantigen. Although, this technologyhas provided a robust platform for launching novel and successful treatments against a varietyof devastating diseases, it isup tillnowonlyexceptionally employed in therapyof infectious diseases. Monoclonal antibodies engagedin the treatment of specific cancersseemto work by a dual mode; they mark the cancerous cellsfor decontamination by the immune system, but also block a function that intervenes with cell growth. The availability of the entire genome sequence of pathogens has stronglyfacilitatedthe identification ofhighlyspecific protein antigensthat aresuitabletargetsfor neutralizingantibodies,but alsooften seemto playan important role in the microbe's life cycle. Thus, the growingrepertoire of well-characterized protein antigenswill open the perspective to developmonoclonal antibodiesagainstbacterial infections.at leastaslast resort treatment, when vaccinationand antibioticsare no options for prevention or therapy. In the following chapterwe describeand comparevarioustechnologies regardingthe identificationof suitabletarget antigens and the foundation ofcognatemonoclonal antibodies and discuss their possible applications in the treatment ofbacterialinfectionstogether with an overview of current efforts.
Proteomics Technology Applied to Upstream and Downstream Process Development of a Protein Vaccine
D evelopment and manufacturing of recombinant-protein–based vaccines has in the past few years become very similar to that of other well-documented and well-characterized biological drugs. For investigational vaccines, chemistry, manufacturing, and controls (CMC) information is critical for a successful regulatory filing. The process development and CGMP manufacturing of a recombinant protein drug is on the critical path toward clinical phase 1 dosing and safety studies as well as proof-of-concept clinical studies (1, 2). However, resources invested in this process may be wasted if the methods and results are not sufficiently documented. Here we describe how proteomics technology has enabled a scientific, risk-based framework for implementing process analytical technology (PAT) in the development of a well-characterized protein vaccine. Our aim is to identify the scientific tools that support innovation in process development and to exemplify the strategy for regulatory implementati...
A Novel Protective Vaccine Antigen from the Core Escherichia coli Genome
mSphere, 2016
Escherichia coli is a versatile pathogen capable of causing intestinal and extraintestinal infections that result in a huge burden of global human disease. The diversity of E. coli is reflected by its multiple different pathotypes and mosaic genome composition. E. coli strains are also a major driver of antibiotic resistance, emphasizing the urgent need for new treatment and prevention measures. Here, we used a large data set comprising 1,700 draft and complete genomes to define the core and accessory genome of E. coli and demonstrated the overlapping relationship between strains from different pathotypes. In combination with proteomic investigation, this analysis revealed core genes that encode surface-exposed or secreted proteins that represent potential broad-coverage vaccine antigens. One of these antigens, YncE, was characterized as a conserved immunogenic antigen able to protect against acute systemic infection in mice after vaccination. Overall, this work provides a genomic b...
Advanced strategies for development of vaccines against human bacterial pathogens
World Journal of Microbiology and Biotechnology, 2021
Infectious diseases are one of the main grounds of death and disabilities in human beings globally. Lack of effective treatment and immunization for many deadly infectious diseases and emerging drug resistance in pathogens underlines the need to either develop new vaccines or sufficiently improve the effectiveness of currently available drugs and vaccines. In this review, we discuss the application of advanced tools like bioinformatics, genomics, proteomics and associated techniques for a rational vaccine design.
In silico Designing of an Epitope-Based Vaccine Against Common E. coli Pathotypes
Frontiers in Medicine, 2022
Escherichia coli (E. coli) is a Gram-negative bacterium that belongs to the family Enterobacteriaceae. While E. coli can stay as an innocuous resident in the digestive tract, it can cause a group of symptoms ranging from diarrhea to live threatening complications. Due to the increased rate of antibiotic resistance worldwide, the development of an effective vaccine against E. coli pathotypes is a major health priority. In this study, a reverse vaccinology approach along with immunoinformatics has been applied for the detection of potential antigens to develop an effective vaccine. Based on our screening of 5,155 proteins, we identified lipopolysaccharide assembly protein (LptD) and outer membrane protein assembly factor (BamA) as vaccine candidates for the current study. The conservancy of these proteins in the main E. coli pathotypes was assessed through BLASTp to make sure that the designed vaccine will be protective against major E. coli pathotypes. The multitope vaccine was const...
Review on Novel Bacterial Antigen Identification Methods for the Development of Candidate Vaccine
Journal of Vaccines and Vaccination, 2021
This review mainly focused on methods that are used for identifying novel bacterial antigens that can use in recombinant subunit vaccine development. Particularly, it describes the processes involved in reverse vaccinology, genomic function, bioinformatics and immunological approaches and some associated complementary technologies such as proteomics that can be used in identification of new and potentially useful vaccine antigens. Results obtained from the application of these methods are forming basis for a new generation of vaccine for use in the control of bacterial infections of humans and animals.